English中文

What is Liquid Biopsy?  


    Cancer detection and monitoring method


    Liquid Biopsy, also known as fluid biopsy, is a significant branch of in vitro diagnosis that is primarily based on blood or other body fluid for disease analysis and monitoring, such as cancer. With a simple blood draw, circulating tumor biomarkers in the blood sample provide information on tumor progression and treatment efficacy, and guiding personalized precision medication direction. Compared with traditional tissue biopsy, liquid biopsy has provided additional benefits of real-time monitoring, avoid unrepresentative sampling in heterogenous tumor, and provides comprehensive clinical information.


    Liquid Biopsy is a branch of in vitro diagnostics that analyses and diagnoses diseases such as cancer through the use of body liquids like blood or urine. It was rated as one of the “Breakthrough Technologies 2015” by MIT Technology Review.


    Compared to traditional tissue biopsy, liquid biopsy is equipped with unique advantages like real-time monitoring, ability to overcome tumor heterogeneity, and comprehensive diagnostic information. Currently, in clinical researches, liquid biosy mainly includes tests for CTC (Circulating Tumor Cell), ctDNA (Circulating Tumor DNA), exosomes, and Circulating miRNA etc. In comparison to traditional methods like observation of clinical symptoms or diagnostic imaging, using liquid biopsy can predict the risk of cancer earlier, enabling “Early discovery, early screening, early treatment”.


What is Circulating miRNA?


microRNAs or miRNAs are small RNA molecules that are non-coding and have important effects on gene expression, often inhibitory.  By binding to mRNAs in the cells, the microRNAs inhibit DNA functioning, thus affecting important life functions in a cell. In many cancer types, miRNAs production is upregulated, converting an ordinary cell into a cancerous one. Additionally, these miRNAs can be transported outside the cell, in the tumour environment, in sacs/vesicles called 'exosomes'. The presence of a high number of exosomal miRNAs has been associated with the spread of certain types of cancer in the body. Isolation and detection of miRNAs from a patient’s blood can help in early cancer diagnosis, without the need for invasive surgeries.

What is Circulating Tumor Cell (CTC)?


Circulating tumor cell (CTCs) are the cancer cells that have detached from the primary tumor or metastatic tumor into circulatory system during tumor progression or metastases. CTC provides comprehensive information of cancer in cellular, genetics and protein levels. Hence, CTC detection is an effective tool for earlier detection, evaluation of therapeutic efficacy, individual precision medicine selection, drug resistance detection, earlier tumor recurrence evaluation and real-time monitoring of cancer.


How can we detect CTCs in blood?


Cellomics CTC detection Platform - New generation of CTC viable Cell Sorting.


The CTC detection platform has employed the leading microfluidic chip technology that select CTCs extensively by cell size, cell shape and multiple surface biomarkers. This technology has combined the physical, chemical and biological properties of CTCs to uphold the high sensitivity, high specificity and high accuracy of CTC detection.



Cellomics International CEO, Christine Huang, listed in Forbes China’s 30 under 30, 2020

Time: 2020-12-02 15:39:24

Author: Cellomics Holdings Limited

Click: 57

​Hong Kong, Nov 11th, 2020 – Cellomics International, a Biotechnology spin-off company from the City University of Hong Kong, today announced that Christine Huang, co-founder and chief executive offic



Christine Huang, CEO, Cellomics International


Hong Kong, Nov 11th, 2020 – Cellomics International, a Biotechnology spin-off company from the City University of Hong Kong, today announced that Christine Huang, co-founder and chief executive officer of Cellomics International has been listed in Forbes China’s 30 under 30. Huang is among 30 game changers and pioneers who have worked persistently in the field of science and medical technology, revolutionizing the industry.

 

Huang co-founded two biotechnology companies based on cancer diagnostics and cancer immunotherapy before the age of 26, while concurrently holding a senior research position at the City University of Hong Kong, and a certification in Venture Finance from Oxford University. She is devoted to bringing cutting-edge technology from laboratory to clinical use and further commercialization, to help people facing life-threatening illnesses. In addition to her strong research and business experience, Christine was a clinician at Queen Mary Hospital from 2015 to end of 2017 following her Master’s Degree in Public Health. In her current role as the Director / CEO of Cellomics International Limited, Christine leads an award-winning team that has developed an early cancer detection technique using liquid biopsy, presently having benefitted over 2000 patients in Asia.

 

Despite a robust selection criteria and a difficult year in regards to the Covid-19 pandemic, Christine was nominated by the leading consulting company, Deloitte, for her work in making early cancer detection more accessible around the world. On 9th November, Christine went on the receiving the honour of being listed in Forbes China’s 30 under 30. More details about the Forbes report are available at https://mp.weixin.qq.com/s/Wswc-Fws7h4tCqUUWxadLQ .

 

 

About Cellomics International:

Cellomics is a leading biotech company based in the Greater-Bay-Area, focusing on the development and commercialization of liquid biopsy products and services for early screening and disease management of cancer. With proprietary microfluidics and nucleic acid detection technology, we offer comprehensive liquid biopsy solutions for precision oncology which only require one blood draw of 4 ml. Our innovative products for circulating tumour cell enrichment and genetic analysis are manufactured in ISO13485 & ISO9001- certified facilities and are approved for clinical use in China and European markets. Additionally, with the use of our technology we aid doctors to test drug sensitivity and help patients identify the most appropriate medication.  Cellomics has obtained over 10 million HKD in funding from the HK government, as well as raising over 70 million HKD (10 million USD) in private/institutional funding. Cellomics aspires to become a global leader in liquid biopsy and precision medicine, and collaborating with international partners to help doctors and patients in winning the war against cancer.

 

 

 

Connect With Us!

Facebook: Cellomics International

Instagram: Cellomics International (username - cellomicsbio)

Twitter: Cellomics International (username - cellomicsbio)

LinkedIn: Cellomics International

 


Cellomics International CEO, Christine Huang, listed in Forbes China’s 30 under 30, 2020
​Hong Kong, Nov 11th, 2020 – Cellomics International, a Biotechnology spin-off company from the City University of Hong Kong, today announced that Christine Huang, co-founder and chief executive offic
Long by picture save/share
图片展示

Product 

CTC 100 Sorter

CTC PreDX

CTCMntDX

CTCImmunoDx

About 

The Team

Awards

News

Blog

Contact Us

Email: info@cellomicsbio.com

Tel: +86-0755-28378001

1

Copyright © 2020 Cellomics All Rights Reserved

Copyright © 2020 Cellomics All Rights Reserved